Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
Baxter
Mallinckrodt
Dow

Last Updated: August 17, 2022

STRIANT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Striant, and when can generic versions of Striant launch?

Striant is a drug marketed by Auxilium Pharms Llc and is included in one NDA.

The generic ingredient in STRIANT is testosterone. There are sixty-nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Striant

A generic version of STRIANT was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.

  Try it Free

US Patents and Regulatory Information for STRIANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Auxilium Pharms Llc STRIANT testosterone TABLET, EXTENDED RELEASE;BUCCAL 021543-001 Jun 19, 2003 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for STRIANT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Auxilium Pharms Llc STRIANT testosterone TABLET, EXTENDED RELEASE;BUCCAL 021543-001 Jun 19, 2003 See Plans and Pricing See Plans and Pricing
Auxilium Pharms Llc STRIANT testosterone TABLET, EXTENDED RELEASE;BUCCAL 021543-001 Jun 19, 2003 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for STRIANT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Warner Chilcott UK Ltd. Intrinsa testosterone EMEA/H/C/000634
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
Warner Chilcott  Deutschland GmbH Livensa testosterone EMEA/H/C/000630
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for STRIANT

See the table below for patents covering STRIANT around the world.

Country Patent Number Title Estimated Expiration
Romania 120814 COMPOZIŢIE FARMACEUTICĂ PENTRU TRATAREA DISMENOREEI ŞI A NAŞTERII PREMATURE ŞI UTILIZAREA ACESTEIA (PHARMACEUTICAL COMPOSITION FOR TREATING DYSMENORRHEA AND PREMATURE LABOUR AND USE THEREOF) See Plans and Pricing
Argentina 016650 UNA COMPOSICION FARMACEUTICA PARA ADMISTRACIoN VAGINAL Y SU USO See Plans and Pricing
Norway 329203 See Plans and Pricing
Malaysia 128628 BIOADHESIVE PROGRESSIVE HYDRATION TABLETS See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Harvard Business School
Baxter
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.